Dr. Feldman on Remaining Challenges With Biomarkers in Prostate Cancer

Adam Scott Feldman, MD, MPH
Published: Friday, Aug 18, 2017



Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

There is a plethora of research on biomarkers, but the ones that actually affect clinical care is quite small, says Feldman.
 


Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

There is a plethora of research on biomarkers, but the ones that actually affect clinical care is quite small, says Feldman.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x